BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + Etoposide
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-Stage Small Cell Lung Cancer
Conditions
Extensive-Stage Small Cell Lung Cancer
Trial Timeline
Feb 25, 2025 → Sep 5, 2031
NCT ID
NCT06646276About BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + Etoposide
BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + Etoposide is a phase 3 stage product being developed by Bristol Myers Squibb for Extensive-Stage Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06646276. Target conditions include Extensive-Stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Extensive-Stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (5)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06646276 | Phase 3 | Recruiting |
Competing Products
20 competing products in Extensive-Stage Small Cell Lung Cancer